Topical treatment with nerve growth factor for neurotrophic keratitis

被引:242
作者
Bonini, S
Lambiase, A
Rama, P
Caprioglio, G
Aloe, L
机构
[1] Univ Roma Tor Vergata, Dept Ophthalmol, I-00100 Rome, Italy
[2] GB Bietti Eye Fdn, Rome, Italy
[3] CNR, Inst Neurobiol, Rome, Italy
[4] Hosp Venice SS Giovanni & Paolo, Div Ophthalmol, Venice, Italy
关键词
D O I
10.1016/S0161-6420(00)00163-9
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objective: To evaluate the efficacy of nerve growth factor (NGF) in patients with neurotrophic keratitis. Design: Prospective, noncomparative, interventional case series. Participants: Forty-five eyes of 43 consecutive patients with moderate (stage 2, n = 17) to severe (stage 3, n = 28) neurotrophic keratitis unresponsive to other nonsurgical therapies. Methods: After a 10-day washout with preservative-free artificial tears, 45 eyes with neurotrophic keratitis received murine NGF (200 mu g/ml) every 2 hours for 2 days followed by one drop six times daily until the ulcer healed. A maintenance dose of one drop NGF (100 mu g/ml) was administered four times daily for the 2 weeks subsequent to ulcer healing. Main Outcome Measures: Size and depth of the ulcer or the epithelial defect, corneal sensitivity, best corrected visual acuity, side effects, and relapse of the disease in the follow-up period. Results: All patients had a complete resolution of the persistent epithelial defect (with or without an ulcer) after 12 days to 6 weeks of treatment with NGF. Patients affected by both stages of the disease demonstrated both improved corneal sensitivity and visual acuity (P < 0.001). No significant differences were observed in the time to complete corneal healing between stage 2 and stage 3 patients. Hyperemia and ocular and periocular pain were side effects reported during the first days of treatment. No relapse of the disease was observed during the follow-up period, with the exception of three patients with trigeminal nerve resection, who required a single retreatment. Conclusions: Nerve growth factor eye drops improved corneal sensitivity and promoted corneal epithelial healing in both moderate and severe neurotrophic keratitis. Although performed in an uncontrolled and nonrandomized series of patients, this therapy shows promise for the restoration of ocular surface integrity and visual function in neurotrophic corneal disease. (C) 2000 by the American Academy of Ophthalmology.
引用
收藏
页码:1347 / 1351
页数:5
相关论文
共 31 条
[1]   The expanding role of nerve growth factor: from neurotrophic activity to immunologic diseases [J].
Aloe, L ;
BracciLaudiero, L ;
Bonini, S ;
Manni, L .
ALLERGY, 1997, 52 (09) :883-894
[2]   NERVE GROWTH-FACTOR REGULATES NOCICEPTION IN HUMAN HEALTH AND DISEASE [J].
ANAND, P .
BRITISH JOURNAL OF ANAESTHESIA, 1995, 75 (02) :201-208
[3]   DEPLETION OF NERVE GROWTH-FACTOR IN LEPROSY [J].
ANAND, P ;
PANDYA, S ;
LADIWALA, U ;
SINGHAL, B ;
SINICROPI, DV ;
WILLIAMSCHESTNUT, RE .
LANCET, 1994, 344 (8915) :129-130
[4]  
Apfel SC, 1999, BRAIN PATHOL, V9, P393
[5]   NERVE GROWTH FACTOR - PURIFICATION AS A 30,000-MOLECULAR-WEIGHT PROTEIN [J].
BOCCHINI, V ;
ANGELETTI, PU .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1969, 64 (02) :787-+
[6]   DIABETIC NEUROPATHY, NERVE GROWTH-FACTOR AND OTHER NEUROTROPHIC FACTORS [J].
BREWSTER, WJ ;
FERNYHOUGH, P ;
DIEMEL, LT ;
MOHIUDDIN, L ;
TOMLINSON, DR .
TRENDS IN NEUROSCIENCES, 1994, 17 (08) :321-325
[7]  
CAVANAGH HD, 1989, ACTA OPHTHALMOL, V67, P115
[8]   Treatment of neurotrophic keratopathy with substance-P-derived peptide (FGLM) and insulin-like growth factor I [J].
Chikama, T ;
Fukuda, K ;
Morishige, N ;
Nishida, T .
LANCET, 1998, 351 (9118) :1783-1784
[9]   INCREASED CONTENT AND TRANSPORT OF SUBSTANCE-P AND CALCITONIN GENE-RELATED PEPTIDE IN SENSORY NERVES INNERVATING INFLAMED TISSUE - EVIDENCE FOR A REGULATORY FUNCTION OF NERVE GROWTH-FACTOR INVIVO [J].
DONNERER, J ;
SCHULIGOI, R ;
STEIN, C .
NEUROSCIENCE, 1992, 49 (03) :693-698
[10]   MANAGEMENT OF NONINFECTIOUS CORNEAL ULCERS [J].
DONZIS, PB ;
MONDINO, BJ .
SURVEY OF OPHTHALMOLOGY, 1987, 32 (02) :94-110